Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
VG-3927 by Vigil Neuroscience for Alzheimer's Disease: Likelihood of Approval
VG-3927 is under clinical development by Vigil Neuroscience and currently in Phase I for Alzheimer's Disease. According to GlobalData, Phase...